(90)Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

Despite significant advances in the treatment of Hodgkin’s lymphoma (HL), a significant proportion of patients will not respond or will subsequently relapse. We identified CD25, the IL-2 receptor alpha subunit, as a favorable target for systemic radioimmunotherapy of HL. The scientific basis for the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Janik, John E., Morris, John C., O’Mahony, Deirdre, Pittaluga, Stefania, Jaffe, Elaine S., Redon, Christophe E., Bonner, William M., Brechbiel, Martin W., Paik, Chang H., Whatley, Millie, Chen, Clara, Lee, Jae-Ho, Fleisher, Thomas A., Brown, Maggie, White, Jeffrey D., Stewart, Donn M., Fioravanti, Suzanne, Lee, Cathryn C., Goldman, Carolyn K., Bryant, Bonita R., Junghans, Richard P., Carrasquillo, Jorge A., Worthy, Tat’Yana, Corcoran, Erin, Conlon, Kevin C., Waldmann, Thomas A.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2015
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4620907/
https://ncbi.nlm.nih.gov/pubmed/26438866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1516107112
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados